The two defendants are Miguel Angel Montalvo Villa, 53, the CEO and co-owner of AMB Research Center, and Ivette Maria Portela Martinez, 53, a pharmacist and data entry specialist at the clinic. From 2015 to 2018, the two enrolled patients without their consent into a clinical trial for an experimental drug for Clostridium difficile-associated diarrhea.
The patients did not have CDAD, but Mr. Montalvo and Ms. Portela falsified hundreds of documents into clinical trial databases, according to the Justice Department.
Their sentencing is scheduled for Nov. 30.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
